CCM
LCTX icon

CTC Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

CTC Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$21.1K Buy
+14,100
New +$19.7K 0.04% 69

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CTC Capital Management's LCTX Position: Q1 2023 in Review

CTC Capital Management opened a new position in Lineage Cell Therapeutics (LCTX) in Q1 2023: 14,100 shares worth $21.1K. The stake represents 0.04% of the portfolio and ranks #69 among its holdings.

115 funds tracked by Wall St. Rank hold LCTX as of Q1 2023.

  • CTC Capital Management held 14,100 shares of Lineage Cell Therapeutics worth $21.1K as of Q1 2023.
  • Lineage Cell Therapeutics was a new CTC Capital Management position in Q1 2023.
  • Lineage Cell Therapeutics made up 0.04% of CTC Capital Management's portfolio in Q1 2023, its #69 holding.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2023.

Based on CTC Capital Management's 13F filing for Q1 2023, filed 5 May 2023.